Oxidized high-density lipoprotein is associated with increased plasma glucose in non-diabetic dyslipidemic subjects

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 125-129

  Kotani, Kazuhiko ^a,b,c   Sakane, Naoki ^a   Ueda, Masashi ^d   Mashiba, Shinichi ^d   Hayase, Yasuyuki ^d   Tsuzaki, Kokoro ^a   Yamada, Toshiyuki ^b   Remaley, Alan T ^c  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Ikagaku Co Ltd   (Japan)

Author keywords

Atherosclerosis; Hyperlipidemia; LDL particle size; Oxidative stress; Small dense LDL

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; OXIDATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; RISK ASSESSMENT; RISK FACTOR; BLOOD; BODY MASS; CHEMISTRY; MIDDLE AGED; OXIDATION REDUCTION REACTION; REGRESSION ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; IMMUNOPRECIPITATION; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; REGRESSION ANALYSIS;

EID: 84866523977     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.08.021     Document Type: Article

References (47)

1. Deaton, C., Froelicher, E.S., Wu, L.H., Ho, C., Shishani, K., Jaarsma, T., The global burden of cardiovascular disease. Eur J Cardiovasc Nurs 10 (2011), S5–S13.
2. Davidson, M.H., Focusing on high-density lipoprotein for coronary heart disease risk reduction. Cardiol Clin 29 (2011), 105–122.
3. Navab, M., Reddy, S.T., Van Lenten, B.J., Fogelman, A.M., HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8 (2011), 222–232.
4. Nakajima, T., Origuchi, N., Matsunaga, T., et al. Localization of oxidized HDL in atheromatous plaques and oxidized HDL binding sites on human aortic endothelial cells. Ann Clin Biochem 37 (2000), 179–186.
5. Thorne, R.F., Mhaidat, N.M., Ralston, K.J., Burns, G.F., CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. FEBS Lett 581 (2007), 1227–1232.
6. Witztum, J.L., Steinberg, D., The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc Med 11 (2001), 93–102.
7. Matsunaga, T., Koyama, I., Hokari, S., Komoda, T., Detection of oxidized high-density lipoprotein. J Chromatogr B Analyt Technol Biomed Life Sci 781 (2002), 331–343.
8. Bowry, V.W., Stanley, K.K., Stocker, R., High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 89 (1992), 10316–10320.
9. Shao, B., Oda, M.N., Vaisar, T., Oram, J.F., Heinecke, J.W., Pathways for oxidation of high-density lipoprotein in human cardiovascular disease. Curr Opin Mol Ther 8 (2006), 198–205.
10. Pankhurst, G., Wang, X.L., Wilcken, D.E., et al. Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J Lipid Res 44 (2003), 349–355.
11. Zheng, L., Nukuna, B., Brennan, M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114 (2004), 529–541.
12. von Eckardstein, A., Walter, M., Holz, H., Benninghoven, A., Assmann, G., Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III. J Lipid Res 32 (1991), 1465–1476.
13. Francis, G.A., High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 1483 (2000), 217–235.
14. Nakano, T., Nagata, A., Oxidative susceptibility of apolipoprotein AI in serum. Clin Chim Acta 362 (2005), 119–124.
15. Ohmura, H., Watanabe, Y., Hatsumi, C., et al. Possible role of high susceptibility of high-density lipoprotein to lipid peroxidative modification and oxidized high-density lipoprotein in genesis of coronary artery spasm. Atherosclerosis 142 (1999), 179–184.
16. Chen, N.G., Azhar, S., Abbasi, F., Carantoni, M., Reaven, G.M., The relationship between plasma glucose and insulin responses to oral glucose, LDL oxidation, and soluble intercellular adhesion molecule-1 in healthy volunteers. Atherosclerosis 152 (2000), 203–208.
17. Younis, N., Charlton-Menys, V., Sharma, R., Soran, H., Durrington, P.N., Glycation of LDL in non-diabetic people: small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 202 (2009), 162–168.
18. Jenkins, A.J., Rowley, K.G., Lyons, T.J., Best, J.D., Hill, M.A., Klein, R.L., Lipoproteins and diabetic microvascular complications. Curr Pharm Des 10 (2004), 3395–3418.
19. Soran, H., Durrington, P.N., Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 22 (2011), 254–261.
20. Ueda, M., Hayase, Y., Mashiba, S., Establishment and evaluation of 2 monoclonal antibodies against oxidized apolipoprotein A-I (apoA-I) and its application to determine blood oxidized apoA-I concentrations. Clin Chim Acta 378 (2007), 105–111.
21. Honda, H., Ueda, M., Kojima, S., et al. Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients. Clin J Am Soc Nephrol 5 (2010), 1021–1028.
22. Honda, H., Ueda, M., Kojima, S., et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 220 (2012), 493–501.
23. Teramoto, T., Sasaki, J., Ueshima, H., et al. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14 (2007), 155–158.
24. World Health Organization, Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006, World Health Organization, Geneva.
25. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 35 (2012), S64–S71.
26. Tsuzaki, K., Kotani, K., Fujiwara, S., et al. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene is associated with increased small dense low-density lipoprotein in a rural Japanese population: the Mima study. Metabolism 56 (2007), 1689–1693.
27. Sakai, J., Nohturfft, A., Cheng, D., Ho, Y.K., Brown, M.S., Goldstein, J.L., Identification of complexes between the COOH-terminal domains of sterol regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating protein. J Biol Chem 272 (1997), 20213–20221.
28. Havel, R.J., Eder, H.A., Bragdon, J.H., The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955), 1345–1353.
29. Kobayashi, J., Murano, S., Kawamura, I., et al. The relationship of percent body fat by bioelectrical impedance analysis with blood pressure, and glucose and lipid parameters. J Atheroscler Thromb 13 (2006), 221–226.
30. No authorsLipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation 86 (1992), 839–848.
31. McBride, P., Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 10 (2008), 386–390.
32. Rashid, S., Trinh, D.K., Uffelman, K.D., Cohn, J.S., Rader, D.J., Lewis, G.F., Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native high-density lipoprotein apolipoprotein A-I. Circulation 107 (2003), 3066–3072.
33. Barter, P.J., Brewer, H.B. Jr., Chapman, M.J., Hennekens, C.H., Rader, D.J., Tall, A.R., Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003), 160–167.
34. Tsimihodimos, V., Gazi, I., Kostara, C., Tselepis, A.D., Elisaf, M., Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids 42 (2007), 403–409.
35. Packard, C.J., Shepherd, J., Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17 (1997), 3542–3546.
36. Rizzo, M., Berneis, K., Low-density lipoprotein size and cardiovascular risk assessment. QJM 99 (2006), 1–14.
37. Berneis, K.K., Krauss, R.M., Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002), 1363–1379.
38. Hanna-Moussa, A., Gardner, M.J., Kurukulasuriya, L.R., Sowers, J.R., Dysglycemia/prediabetes and cardiovascular risk factors. Rev Cardiovasc Med 10 (2009), 202–208.
39. Maytin, M., Leopold, J., Loscalzo, J., Oxidant stress in the vasculature. Curr Atheroscler Rep 1 (1999), 156–164.
40. Vergès, B., Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 23 (2009), 681–685.
41. Calvo, C., Talussot, C., Ponsin, G., Berthézène, F., Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties. Biochem Biophys Res Commun 153 (1988), 1060–1067.
42. Calvo, C., Ponsin, G., Berthezene, F., Characterization of the non enzymatic glycation of high density lipoprotein in diabetic patients. Diabete Metab 14 (1988), 264–269.
43. Duell, P.B., Oram, J.F., Bierman, E.L., Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 40 (1991), 377–384.
44. Lyons, T.J., Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 71 (1993), 26B–31B.
45. Quintao EC 2000, Quintão, E.C., Medina, W.L., Passarelli, M., Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 16 (2000), 237–250.
46. Nobécourt, E., Jacqueminet, S., Hansel, B., et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48 (2005), 529–538.
47. Grattagliano, I., Palmieri, V.O., Portincasa, P., Moschetta, A., Palasciano, G., Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 19 (2008), 491–504.